Strata Critical Medical (SRTA) Enterprise Value (2019 - 2026)

Strata Critical Medical has disclosed Enterprise Value across 8 years of filings, most recently posting -$58.8 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 51.01% year-over-year to -$58.8 million; the TTM figure through Mar 2026 stood at -$58.8 million (up 51.01% YoY), while the FY2025 annual figure was -$61.2 million, up 50.95% from the prior year.
• Enterprise Value rose to -$58.8 million in Q1 2026, from -$61.2 million in the prior quarter.
• Over the last five years, Enterprise Value for SRTA reached as high as -$53.4 million in Q3 2025 and fell as low as -$269.1 million in Q1 2022.
• The 5-year median for Enterprise Value is -$142.0 million (2024), against an average of -$147.1 million.
• Annual changes were most pronounced in 2022 — Enterprise Value plunged 3482.16% — and 2025, when it surged 60.81%.
• A 5-year view of Enterprise Value shows it stood at -$153.8 million in 2022, then rose by 9.37% to -$139.4 million in 2023, then advanced by 10.46% to -$124.8 million in 2024, then soared by 50.95% to -$61.2 million in 2025, then increased by 3.99% to -$58.8 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$58.8 million, -$61.2 million, and -$53.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.